AI Engines For more Details: Perplexity Kagi Labs You
Regulation of Metabolism: Corticosterone is involved in regulating glucose metabolism. It stimulates gluconeogenesis, the process by which glucose is synthesized from non-carbohydrate sources like amino acids and fats. This helps maintain adequate blood glucose levels, especially during periods of fasting or stress.
Anti-inflammatory Effects: Like other glucocorticoids, corticosterone has potent anti-inflammatory and immunosuppressive properties. It suppresses the immune response by inhibiting the production of pro-inflammatory cytokines and other mediators of inflammation. This action is important for controlling inflammation and preventing tissue damage.
Stress Response: Corticosterone is a key component of the body's stress response system. In response to stressors such as physical trauma, infection, or psychological stress, corticosterone levels rise to help the body cope with the stress. It mobilizes energy reserves, suppresses unnecessary bodily functions, and enhances the body's ability to respond to the stressor.
Regulation of Blood Pressure: Corticosterone plays a role in regulating blood pressure and fluid balance. It increases sodium reabsorption in the kidneys, leading to water retention and increased blood volume. This contributes to the maintenance of blood pressure and electrolyte balance.
Role in Development: During development, corticosterone plays a role in the maturation of various organs and systems, including the brain. It can have long-lasting effects on brain structure and function, influencing behaviors such as cognition, mood, and stress responsiveness.
Modulation of Sleep-Wake Cycle: Corticosterone levels exhibit diurnal variation, with peak levels occurring in the morning and lower levels at night. This hormonal rhythm is important for regulating the sleep-wake cycle and maintaining normal circadian rhythms.
Impact on Mood and Behavior: Dysregulation of corticosterone levels has been implicated in mood disorders such as depression and anxiety. Chronic stress and elevated corticosterone levels may contribute to the development or exacerbation of these conditions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.2 | -0.2 | |
| ADHD | 2.1 | 0.1 | 20 |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.9 | -2 |
| Allergies | 1.3 | 0.8 | 0.63 |
| Allergy to milk products | 0.3 | 0.2 | 0.5 |
| Alopecia (Hair Loss) | 0.4 | 0.4 | |
| Alzheimer's disease | 1 | 1.4 | -0.4 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.1 | 4 |
| Ankylosing spondylitis | 1 | 0.4 | 1.5 |
| Anorexia Nervosa | 0.7 | -0.7 | |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 0.2 | 0.3 | -0.5 |
| Atherosclerosis | 0.5 | 0.4 | 0.25 |
| Atrial fibrillation | 1.2 | 0.6 | 1 |
| Autism | 1.8 | 2.2 | -0.22 |
| Barrett esophagus cancer | 0.2 | 0.2 | 0 |
| benign prostatic hyperplasia | 0 | 0 | |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 0.3 | 0.3 | 0 |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Cancer (General) | 0.2 | 1.1 | -4.5 |
| Carcinoma | 1.2 | 1 | 0.2 |
| Celiac Disease | 0.7 | 1.2 | -0.71 |
| Cerebral Palsy | 0.4 | 0.5 | -0.25 |
| Chronic Fatigue Syndrome | 2.2 | 2 | 0.1 |
| Chronic Kidney Disease | 0.3 | 0.5 | -0.67 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.1 | 6 |
| Chronic Urticaria (Hives) | 0.3 | 0.2 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 0.2 | 0.5 | -1.5 |
| Colorectal Cancer | 1.3 | 0.4 | 2.25 |
| Constipation | 0.3 | 0.3 | 0 |
| Coronary artery disease | 0.3 | 0.4 | -0.33 |
| COVID-19 | 3.8 | 4.5 | -0.18 |
| Crohn's Disease | 1.6 | 1.4 | 0.14 |
| cystic fibrosis | 0.1 | 0.4 | -3 |
| deep vein thrombosis | 0.1 | 0.2 | -1 |
| Depression | 2.5 | 2.4 | 0.04 |
| Dermatomyositis | 0.2 | 0.2 | 0 |
| Eczema | 0.1 | 0.7 | -6 |
| Endometriosis | 1 | 0.3 | 2.33 |
| Eosinophilic Esophagitis | 0.1 | 0.1 | 0 |
| Epilepsy | 1 | 0.6 | 0.67 |
| Fibromyalgia | 0.5 | 0.8 | -0.6 |
| Functional constipation / chronic idiopathic constipation | 1.5 | 0.9 | 0.67 |
| gallstone disease (gsd) | 0.4 | 0.3 | 0.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.6 | -2 |
| Generalized anxiety disorder | 0.4 | 0.8 | -1 |
| Glioblastoma | 0.2 | -0.2 | |
| Gout | 0.1 | -0.1 | |
| Graves' disease | 0.5 | 0.4 | 0.25 |
| Halitosis | 0.4 | 0.2 | 1 |
| Hashimoto's thyroiditis | 0.7 | 0.4 | 0.75 |
| Hidradenitis Suppurativa | 0.2 | 0.1 | 1 |
| High Histamine/low DAO | 0.1 | 0.2 | -1 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0 | 0.6 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.1 | 2 |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.8 | 1.9 | -1.37 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 1.1 | -1.1 | |
| Inflammatory Bowel Disease | 1.3 | 2 | -0.54 |
| Insomnia | 0.6 | 0.3 | 1 |
| Intelligence | 0.1 | 0.2 | -1 |
| Intracranial aneurysms | 0.5 | 0.1 | 4 |
| Irritable Bowel Syndrome | 0.9 | 1.3 | -0.44 |
| Liver Cirrhosis | 1.4 | 0.9 | 0.56 |
| Long COVID | 2.1 | 2.9 | -0.38 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.2 | 0.3 | -0.5 |
| Mast Cell Issues / mastitis | 0.2 | 0.3 | -0.5 |
| ME/CFS with IBS | 0.2 | 1.1 | -4.5 |
| ME/CFS without IBS | 0.4 | 0.4 | 0 |
| Menopause | 1.5 | 1.5 | |
| Metabolic Syndrome | 1.9 | 2.1 | -0.11 |
| Mood Disorders | 3 | 2.4 | 0.25 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.2 | 2 |
| Multiple Sclerosis | 1.4 | 0.9 | 0.56 |
| Multiple system atrophy (MSA) | 0.1 | 0.5 | -4 |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.4 | 0 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 2.4 | -2.43 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.4 | 0.5 |
| Obesity | 2 | 1.6 | 0.25 |
| obsessive-compulsive disorder | 2.2 | 1.2 | 0.83 |
| Osteoarthritis | 0.6 | 0.1 | 5 |
| Osteoporosis | 0.4 | 0.5 | -0.25 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 2.1 | 1.7 | 0.24 |
| Polycystic ovary syndrome | 0.5 | 0.5 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.5 | 0.5 | |
| primary biliary cholangitis | 0.1 | -0.1 | |
| Psoriasis | 1 | 0.5 | 1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 1 | 0.8 |
| Rosacea | 0.2 | 0 | 0 |
| Schizophrenia | 1.8 | 0.6 | 2 |
| scoliosis | 0.1 | 0.1 | 0 |
| Sjögren syndrome | 1.1 | 1.2 | -0.09 |
| Sleep Apnea | 0.7 | 0.6 | 0.17 |
| Slow gastric motility / Gastroparesis | 0.4 | 0.2 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.2 | 0.5 |
| Stress / posttraumatic stress disorder | 0.6 | 0.7 | -0.17 |
| Systemic Lupus Erythematosus | 1.1 | 0.6 | 0.83 |
| Tic Disorder | 0.2 | 0.5 | -1.5 |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 1.5 | 0.7 | 1.14 |
| Type 2 Diabetes | 1.9 | 1.2 | 0.58 |
| Ulcerative colitis | 0.9 | 1.6 | -0.78 |
| Unhealthy Ageing | 1.2 | 0.7 | 0.71 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.81.24 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.81.24 ]
